Resend - Modeling CARDIO-TTRansform: Potential Outcome & Implications

研报英文原文证据摘录

Resend - Modeling CARDIO-TTRansform: Potential Outcome & Implications

May 17, 2026

properly conducted study to evaluate its drug. PFE is likely to continue

to emphasize its data showing TAF is a strong stabilizer, and as an easy

1/d oral drug with leading market share, suggest it should remain the

preferred treatment option for patients.

Our discussions with TTR-CM-treating cardiologists regarding the

potential CARDIO-TTRansform outcomes and their impact on their

treatment paradigm were frustrating, to say the least.

●They didn't understand the underlying disease biology, the role of

monomers, or the true merits of each therapy.

●They demonstrated indifference to potential longer-term

outcomes in TTR-CM patients since patients are older (which we

found a little offensive) and they blend evidence-based medicine

with non-evidence-based, poorly-informed 'gestalt' (which we

found concerning).

●They were highly convicted in their sloppy views, and much of

their decision-making process for TTR-CM was inconsistent with

our understanding of the underlying biology and fundamentals.

As such, it's hard to extrapolate from their commentary or

predict precisely how the CARDIO-TTRansform results may

impact care broadly.

●While Attruby, in our view, likely offers the strongest event rate HR

(likely due to fastest monomer depletion) along with oral convenience,

BBIO is still battling intensely in a very split and competitive market

– which we expect will continue. We do give the company credit for

the execution thus far in such a challenging specialty, and expect this

momentum to continue.

●Given the size of the TTR-CM market, even a 4-way split means

multiple large blockbuster therapies – where everyone can be happy